Načítá se...
Bisphosphonates and other bone agents for breast cancer
BACKGROUND: Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast‐mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied these agents in both early breast...
Uloženo v:
| Vydáno v: | Cochrane Database Syst Rev |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2017
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6485886/ https://ncbi.nlm.nih.gov/pubmed/29082518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD003474.pub4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|